Abeona Therapeutics (ABEO) Presents at Rodman & Renshaw Conference

Abeona Therapeutics, Inc. (NASDAQ: ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening diseases. The company’s lead programs are ABO-101 and ABO-102, which are adeno-associated virus-based gene therapies for the treatment of Sanfilippo syndrome. Abeona expects to commence clinical trials for these programs later this year. Additionally, the company is developing ABO-201 gene therapy for the treatment of juvenile Batten disease and ABO-301 for the treatment of Fanconi anemia disorder using a novel gene editing method. For more information, visit the company’s website at www.abeonatherapeutics.com.